Navigation Links
Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

LIBERTYVILLE, Ill., June 18 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline.

Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to boost gene expression; 2) Tetracyclines at Paratek Pharmaceuticals to correct gene splicing; and 3) Motor neuron replacement program at California Stem Cell and UCI. These three programs represent an investment of over $16 Million so far to build a SMA drug pipeline.

Quinazoline Program:

In June 2009, the IND-enabling safety studies were completed for the FSMA-directed Quinazoline program. This is the program previously worked on by Vertex Pharmaceuticals and deCODE genetics, and fully funded by Families of SMA.

The next step for this program is to request a pre-IND meeting with the FDA and to prepare the required data package. Families of SMA will be working over the next several months with toxicology and regulatory experts to prepare for this meeting. According to Jill Jarecki, Ph.D., Research Director FSMA, "This meeting will be an exciting milestone for the project, and an essential step in the path towards human clinical trials of the drug candidate."

Motor Neuron Replacement Program:

California Stem Cell (CSC) is preparing for a final FDA pre-IND meeting to take place in mid 2009. This is a critical step on the track to submitting a formal Investigational New Drug (IND) application to the FDA to begin clinical trials in SMA Type I. It is the intent of CSC to gain approval to begin FDA-approved clinical trials for the use of these cells in development of a cell replacement therapy for SMA Type I.

Numerous pre-clinical efficacy studies have been completed, demonstrating that the cells work. The pivotal animal safety study, required to support an application to begin clinical trials, was completed in October 2008. According to Chris Airriess, Ph.D., Chief Operating Officer, California Stem Cell, Inc., "CSC is now preparing for a final FDA pre-IND meeting to take place in mid 2009, keeping us on track for a formal IND application to begin a Phase I/IIA clinical trial in SMA Type I."

Tetracycline Program:

According to Paul Higgins, Ph.D., Director, Inflammation Drug Discovery, Paratek Pharmaceuticals, "FSMA has supported the research at Paratek for the previous three years for our work on tetracycline derivatives as a potential treatment of SMA. These compounds are intended to correct SMN2 splicing and in turn increase SMN protein levels.

Using funding from FSMA to generate the preliminary data for a grant application, Paratek has been awarded a multi-million dollar U01 grant from the NINDS to continue our research that FSMA funded for the past 3 years."

The overall goal for this project is to develop a drug candidate for SMA resulting in an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) within 4 to 5 years.

These three announcements were all made at the 25th Anniversary SMA Conference. A record of over 900 families and researchers were present at the conference.

About Families of SMA:

Families of Spinal Muscular Atrophy is dedicated to creating a treatment and cure by:

Funding and advancing a comprehensive research program; Supporting SMA families through networking, information and services; Improving care for all SMA patients; Educating health professionals and the public about SMA; Enlisting government support for SMA; Embracing all touched by SMA in a caring community.

Our vision is a world where Spinal Muscular Atrophy is treatable and curable.

The goal of the organization for 2009 is to have raised $50 million for SMA research. Families of SMA funds and directs the leading SMA research programs. Families of SMA has created hope for our community that did not exist in 1984. Our support comes from generous individual donations and numerous fundraising events held by volunteer families and our chapters.

Our successful results and progress from basic research to drug discovery programs to clinical trials provides real hope for families and patients:

-Families of SMA has funded 5 multi-center clinical trials for existing drugs that have potential for SMA.

-FSMA has directed and funded the leading new drug development program for a therapy specially designed to treat SMA.

-Families of SMA is building a pipeline of drug discovery programs based on our investments in basic research.

-FSMA has invested significant resources into alternative approaches that show promise to cure SMA.

SOURCE Families of Spinal Muscular Atrophy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
2. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
3. Helping Families Cope After an Injury
4. Health Experts and Families Encourage Annual Childhood Flu Vaccination to Reduce Flu-Related Illnesses and Deaths in Children
5. Actress and Mother Jennifer Garner Kicks Off American Lung Associations Faces of Influenza Awareness Campaign, Encouraging Families to Get Vaccinated Against Influenza
6. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
7. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
8. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
9. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
10. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
11. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
Post Your Comments:
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):